Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27466159
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Atheroscler+Thromb
2016 ; 23
(9
): 1011-25
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Development of Antisense Drugs for Dyslipidemia
#MMPMID27466159
Yamamoto T
; Wada F
; Harada-Shiba M
J Atheroscler Thromb
2016[Sep]; 23
(9
): 1011-25
PMID27466159
show ga
Abnormal elevation of low-density lipoprotein (LDL) and triglyceride-rich
lipoproteins in plasma as well as dysfunction of anti-atherogenic high-density
lipoprotein (HDL) have both been recognized as essential components of the
pathogenesis of atherosclerosis and are classified as dyslipidemia. This review
describes the arc of development of antisense oligonucleotides for the treatment
of dyslipidemia. Chemically-armed antisense candidates can act on various kinds
of transcripts, including mRNA and miRNA, via several different endogenous
antisense mechanisms, and have exhibited potent systemic anti-dyslipidemic
effects. Here, we present specific cutting-edge technologies have recently been
brought into antisense strategies, and describe how they have improved the
potency of antisense drugs in regard to pharmacokinetics and pharmacodynamics. In
addition, we discuss perspectives for the use of armed antisense oligonucleotides
as new clinical options for dyslipidemia, in the light of outcomes of recent
clinical trials and safety concerns indicated by several clinical and preclinical
studies.
free
free
free
